Company Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer.
The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 185 |
| CEO | Alan H. Auerbach |
Contact Details
Address: 10880 Wilshire Blvd., Suite 2150 Los Angeles, California 90024 United States | |
| Phone | (424) 248-6500 |
| Website | pumabiotechnology.com |
Stock Details
| Ticker Symbol | PBYI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001401667 |
| CUSIP Number | 74587V107 |
| ISIN Number | US74587V1070 |
| Employer ID | 77-0683487 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alan H. Auerbach | Founder, Chairman, President, Chief Executive Officer and Secretary |
| Maximo F. Nougues | Chief Financial Officer and Principal Accounting Officer |
| Dr. Alvin F. Wong Pharm.d. | Chief Scientific Officer |
| Douglas Hunt B.Sc., FRAPS | Senior Vice President of Regulatory Affairs, Pharmacovigilance, Medical Affairs and Law |
| Jeffrey Jerome Ludwig | Chief Commercial Officer |
| Mariann Ohanesian | Senior Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 19, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 30, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 18, 2024 | 8-K | Current Report |
| Jan 10, 2024 | 144/A | Filing |